Blog

EmpaSug-SM-25-100-500 SR Tablets – Triple Therapy for Type 2 Diabetes Management

• 27-02-2026

Managing type 2 diabetes mellitus (T2DM) often requires more than lifestyle modification alone. When diet, exercise, and dual therapy fail to provide adequate glycemic control, a scientifically designed triple combination can deliver superior outcomes.

EmpaSug-SM-25-100-500 SR Tablets combine Empagliflozin 25mg, Sitagliptin 100mg, and Metformin Hydrochloride 500mg (Sustained Release) to provide comprehensive blood sugar control through three complementary mechanisms of action.

Composition

• Empagliflozin 25mg

• Sitagliptin 100mg

• Metformin Hydrochloride 500mg (SR)

This optimized fixed-dose combination is formulated to improve glycemic control while enhancing patient compliance.

How EmpaSug-SM-25-100-500 SR Works

Empagliflozin (SGLT2 Inhibitor)

Empagliflozin reduces blood glucose by promoting urinary glucose excretion. It works independently of insulin and also supports modest weight reduction.

Sitagliptin (DPP-4 Inhibitor)

Sitagliptin increases incretin hormone levels, enhancing insulin secretion and decreasing glucagon release in a glucose-dependent manner.

Metformin (Biguanide – Sustained Release)

Metformin decreases hepatic glucose production, improves insulin sensitivity, and reduces intestinal glucose absorption. The SR formulation ensures prolonged glycemic control with better gastrointestinal tolerability.

Together, these three agents offer a triple-action mechanism for improved HbA1c reduction and overall metabolic balance.

Indications

EmpaSug-SM-25-100-500 SR Tablets are indicated for:

• Management of Type 2 Diabetes Mellitus

• Patients inadequately controlled on dual therapy

• Adults requiring intensified oral antidiabetic treatment

• Individuals not achieving glycemic targets with lifestyle modification alone

Key Benefits

• ? Comprehensive triple mechanism glucose control

• ? Improved HbA1c reduction

• ? Sustained release formulation for steady blood sugar management

• ? Convenient once-daily dosing (as prescribed)

• ? Enhanced patient compliance

• ? Suitable for long-term diabetes management

Why Choose EmpaSug-SM-25-100-500 SR Tablets?

This advanced combination is ideal for patients requiring stronger glycemic control without transitioning immediately to insulin therapy. The synergy between SGLT2 inhibitor, DPP-4 inhibitor, and Metformin SR ensures optimized therapeutic outcomes while maintaining safety and tolerability.

Packaging Details

• Packing: 10 x 10 Tablets

• Dosage Form: Tablet (SR – Sustained Release)

Conclusion

EmpaSug-SM-25-100-500 SR Tablets represent a modern, evidence-based approach to advanced type 2 diabetes management. By targeting multiple pathophysiological defects of diabetes simultaneously, this triple combination supports better glycemic control, improved patient adherence, and long-term metabolic health.